ATE517633T1 - Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine - Google Patents

Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine

Info

Publication number
ATE517633T1
ATE517633T1 AT03730977T AT03730977T ATE517633T1 AT E517633 T1 ATE517633 T1 AT E517633T1 AT 03730977 T AT03730977 T AT 03730977T AT 03730977 T AT03730977 T AT 03730977T AT E517633 T1 ATE517633 T1 AT E517633T1
Authority
AT
Austria
Prior art keywords
vaccine
apc
composition
cellular
allogeneic
Prior art date
Application number
AT03730977T
Other languages
English (en)
Inventor
Alex Karlsson-Parra
Annacarin Wallgren
Bengt Andersson
Original Assignee
Immunicum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201726A external-priority patent/SE523515C2/sv
Application filed by Immunicum Ab filed Critical Immunicum Ab
Application granted granted Critical
Publication of ATE517633T1 publication Critical patent/ATE517633T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
AT03730977T 2002-06-06 2003-06-05 Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine ATE517633T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38589802P 2002-06-06 2002-06-06
SE0201726A SE523515C2 (sv) 2002-06-06 2002-06-06 Ny metod och komposition för framställning av ett cellulärt allogent vaccin
PCT/SE2003/000936 WO2003103707A1 (en) 2002-06-06 2003-06-05 New method and composition for producing a cellular allogeneic vaccine

Publications (1)

Publication Number Publication Date
ATE517633T1 true ATE517633T1 (de) 2011-08-15

Family

ID=29738554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730977T ATE517633T1 (de) 2002-06-06 2003-06-05 Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine

Country Status (8)

Country Link
US (3) US20050158328A1 (de)
EP (1) EP1509244B1 (de)
AT (1) ATE517633T1 (de)
AU (1) AU2003241252A1 (de)
DK (1) DK1509244T3 (de)
ES (1) ES2369077T3 (de)
SI (1) SI1509244T1 (de)
WO (1) WO2003103707A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1712634A1 (de) * 2005-04-13 2006-10-18 Wittycell SAS Verfahren zur Auswahl von effizienten antigen präsentierenden Zellen und ihre Anwendung in der Regulation der Immunität
US8563307B2 (en) 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
SG174507A1 (en) * 2009-03-24 2011-10-28 Transgene Sa Biomarker for monitoring patients
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
TWI614340B (zh) 2011-09-28 2018-02-11 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
EP2929013B1 (de) 2012-12-06 2020-02-05 Stembios Technologies, Inc. Lgr5+-somatische stammzellen
RU2668816C2 (ru) 2012-12-18 2018-10-02 Иммуникум Аб Совместная дифференцировка моноцитов от аллогенных доноров
EP2746770A1 (de) 2012-12-21 2014-06-25 Stembios Technologies, Inc. Verfahren zur Beurteilung der Wirkung einer Aktion basierend auf Stammzelldynamik auf eine Person
US20190381158A1 (en) * 2016-02-04 2019-12-19 Duke University Cell-based vaccine compositions and methods of use
CN106645669B (zh) * 2016-11-15 2018-11-02 广东海洋大学 一种用于表征鲳鲹巨噬细胞吞噬微生物的方法
PL3460052T3 (pl) 2017-09-20 2020-05-18 Immunicum Ab Ulepszone allogeniczne komórki dendrytyczne do stosowania w leczeniu nowotworu
CN112243382A (zh) * 2018-01-18 2021-01-19 南佛罗里达大学 死抗原刺激的未成熟异源性树突细胞作为疾病治疗剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675703B2 (en) 1993-03-16 1997-02-13 British Technology Group Limited Stimulation of immune response by viral protein
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
ATE389712T1 (de) * 1997-01-31 2008-04-15 Edward P Cohen Krebs immuntherapie mit semi-allogenen zellen
US6251665B1 (en) * 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
CA2322660A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Enhanced anti-tumor immunity
US20020025320A1 (en) * 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
US20020039583A1 (en) * 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7794710B2 (en) * 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness

Also Published As

Publication number Publication date
US20140141046A1 (en) 2014-05-22
US8673296B2 (en) 2014-03-18
AU2003241252A1 (en) 2003-12-22
US20050158328A1 (en) 2005-07-21
EP1509244B1 (de) 2011-07-27
US20070134219A1 (en) 2007-06-14
SI1509244T1 (sl) 2011-11-30
ES2369077T3 (es) 2011-11-25
EP1509244A1 (de) 2005-03-02
WO2003103707A1 (en) 2003-12-18
DK1509244T3 (da) 2011-10-24

Similar Documents

Publication Publication Date Title
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
ATE260971T1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
WO2006047569A3 (en) Methods of expanding myeloid cell populations and uses thereof
ATE455463T1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
ATE367833T1 (de) IN-VITRO-VERFAHREN ZUM HERSTELLEN EINER HOMOLOGEN ßGESTENTETENß TISSUE ENGINEERTEN HERZKLAPPE
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
SG149061A1 (en) Definitive endoderm
ATE411380T1 (de) Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen
WO2003059276A3 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
JP2004536615A5 (de)
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE501264T1 (de) Enzymatische verfahren zur herstellung 4- substituierter 3-hydroxybuttersäure-derivate
MXPA05006042A (es) Administracion de celulas dendriticas parcialmente maduradas in-vitro para el tratamiento de tumores.
NO20053089D0 (no) Carbamidsyreestere med anticolinergisk virkning.
ATE544849T1 (de) Aktivierte dendritische zellen, therapieverfahren unter verwendung der dendritischen zellen sowie verfahren zur kultivierung von gamma-delta-t- zellen
ATE512668T1 (de) Allogenes tumortherapeutikum
DE60042035D1 (de) Verfahren und zusammensetzungen zur herstellung von ophtalmischen linsen
WO2007136760A3 (en) Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
ATE482720T1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
RU2011109546A (ru) Композиции и способы для лечения во время не острых периодов после неврологического повреждения цнс
DK1419240T3 (da) Fremstilling og anvendelse af humane CD124- og CD116-positive tumorcellelinier til fremstilling af allogene eller semi-allogene immumterapeutika
ATE522543T1 (de) Verfahren zur herstellung von reifem, rekombinantem milben-i-allergen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties